Get the Stockscreener App
28.15
2.09%
-0.60
After Hours:
28.08
-0.07
-0.25%
Castle Biosciences Inc stock is traded at $28.15, with a volume of 404.40K.
It is down -2.09% in the last 24 hours and down -1.61% over the past month.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
See More
Previous Close:
$28.75
Open:
$28.82
24h Volume:
404.40K
Relative Volume:
1.02
Market Cap:
$788.41M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-13.09
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
+4.03%
1M Performance:
-1.61%
6M Performance:
+26.35%
1Y Performance:
+20.25%
1-Day Range:
$27.65
$28.87
1-Week Range:
$26.70
$28.90
52-Week Range:
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
28.15 | 788.41M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
580.57 | 222.07B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
215.01 | 154.61B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.04 | 41.95B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
465.03 | 38.08B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
200.04 | 36.31B | 15.32B | 1.41B | 1.96B | 7.62 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Tritonpoint Wealth LLC - MarketBeat
Should You Bet on Castle Biosciences? The Truth Behind Its Stock Struggles! - Jomfruland.net
Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance
Vanguard Group Inc. Increases Stake in Castle Biosciences Inc. - GuruFocus.com
Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet - Yahoo Finance
Leerink Partnrs Issues Optimistic Forecast for CSTL Earnings - Defense World
JPMorgan Chase & Co. Raises Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
FY2024 Earnings Estimate for CSTL Issued By Leerink Partnrs - Defense World
Castle Biosciences (NASDAQ:CSTL) Trading 8.1% HigherTime to Buy? - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Buy" by Brokerages - MarketBeat
Castle Biosciences' DecisionDx-SCC Shows 92% Accuracy in Groundbreaking 1,400-Patient Cancer Study - StockTitan
Despite shrinking by US$214m in the past week, Castle Biosciences (NASDAQ:CSTL) shareholders are still up 29% over 1 year - Simply Wall St
Castle Biosciences CEO Derek Maetzold sells $71,902 in stock - Investing.com India
Derek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $71,902 in stock By Investing.com - Investing.com Australia
Castle Biosciences stock tumbles following guidance concerns - Investing.com India
Castle Biosciences stock tumbles following guidance concerns By Investing.com - Investing.com Nigeria
Castle Biosciences (NASDAQ:CSTL) Trading Down 14%What's Next? - MarketBeat
Barclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Expects 50% Revenue Growth in 2024, Hits Record 96,000 Tests Despite Medicare Setback - StockTitan
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results - Milton Daily Standard
Harbor Capital Advisors Inc. Sells 35,407 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences stock falls following Medicare coverage denial By Investing.com - Investing.com Canada
Castle Biosciences (NASDAQ:CSTL) Shares Gap DownHere's Why - MarketBeat
Castle Biosciences CEO Derek Maetzold sells shares worth $228,066 By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,715 Shares - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 7,867 Shares - MarketBeat
Castle Biosciences' chief commercial officer sells $66,900 in shares By Investing.com - Investing.com Canada
Castle Biosciences’ chief commercial officer sells $66,900 in shares By Investing.com - Investing.com Nigeria
Castle Biosciences director Bradbury sells shares worth $229,225 By Investing.com - Investing.com Australia
Castle Biosciences CEO Derek Maetzold sells shares worth $228,066 - Investing.com India
Castle Biosciences director Bradbury sells shares worth $229,225 - Investing.com
Castle Biosciences (NASDAQ:CSTL) Stock Price Up 6.2%Here's Why - MarketBeat
Castle Biosciences gains NY approval for esophageal test By Investing.com - Investing.com Nigeria
Castle Biosciences gains New York state approval for Barrett’s oesophagus test - Yahoo Finance
Castle Biosciences gains NY approval for esophageal test - Investing.com
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test - Business Wire
Castle Biosciences (NASDAQ:CSTL) Given Overweight Rating at Stephens - Defense World
Castle Biosciences (NASDAQ:CSTL) Earns Overweight Rating from Stephens - MarketBeat
Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock - Benzinga
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.26%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):